rs121918608
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 12P and 1B. PM2PP3_ModeratePP5_Very_StrongBS1_Supporting
The NM_000687.4(AHCY):c.428A>G(p.Tyr143Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000154 in 1,613,226 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000085 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00016 ( 0 hom. )
Consequence
AHCY
NM_000687.4 missense
NM_000687.4 missense
Scores
10
7
2
Clinical Significance
Conservation
PhyloP100: 8.02
Genes affected
AHCY (HGNC:343): (adenosylhomocysteinase) S-adenosylhomocysteine hydrolase belongs to the adenosylhomocysteinase family. It catalyzes the reversible hydrolysis of S-adenosylhomocysteine (AdoHcy) to adenosine (Ado) and L-homocysteine (Hcy). Thus, it regulates the intracellular S-adenosylhomocysteine (SAH) concentration thought to be important for transmethylation reactions. Deficiency in this protein is one of the different causes of hypermethioninemia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 11 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.928
PP5
Variant 20-34292375-T-C is Pathogenic according to our data. Variant chr20-34292375-T-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 12953.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr20-34292375-T-C is described in Lovd as [Pathogenic].
BS1
Variant frequency is greater than expected in population nfe. gnomad4_exome allele frequency = 0.000162 (236/1461002) while in subpopulation NFE AF= 0.000203 (226/1111978). AF 95% confidence interval is 0.000181. There are 0 homozygotes in gnomad4_exome. There are 111 alleles in male gnomad4_exome subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AHCY | NM_000687.4 | c.428A>G | p.Tyr143Cys | missense_variant | 4/10 | ENST00000217426.7 | NP_000678.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AHCY | ENST00000217426.7 | c.428A>G | p.Tyr143Cys | missense_variant | 4/10 | 1 | NM_000687.4 | ENSP00000217426.2 | ||
AHCY | ENST00000538132.1 | c.344A>G | p.Tyr115Cys | missense_variant | 4/10 | 2 | ENSP00000442820.1 | |||
AHCY | ENST00000468908.1 | n.591A>G | non_coding_transcript_exon_variant | 4/5 | 5 | |||||
AHCY | ENST00000480653.5 | n.475A>G | non_coding_transcript_exon_variant | 4/9 | 2 |
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152224Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
13
AN:
152224
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000797 AC: 20AN: 250902Hom.: 0 AF XY: 0.0000958 AC XY: 13AN XY: 135688
GnomAD3 exomes
AF:
AC:
20
AN:
250902
Hom.:
AF XY:
AC XY:
13
AN XY:
135688
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000162 AC: 236AN: 1461002Hom.: 0 Cov.: 32 AF XY: 0.000153 AC XY: 111AN XY: 726812
GnomAD4 exome
AF:
AC:
236
AN:
1461002
Hom.:
Cov.:
32
AF XY:
AC XY:
111
AN XY:
726812
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152224Hom.: 0 Cov.: 33 AF XY: 0.0000672 AC XY: 5AN XY: 74370
GnomAD4 genome
AF:
AC:
13
AN:
152224
Hom.:
Cov.:
33
AF XY:
AC XY:
5
AN XY:
74370
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
0
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
3
ExAC
AF:
AC:
11
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 30, 2023 | Variant summary: AHCY c.428A>G (p.Tyr143Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-05 in 250902 control chromosomes (gnomAD). c.428A>G has been reported in the literature as a biallelic genotype in multiple individuals affected with Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase (e.g. Baric_2004, Baric_2005, Buist_2006), as well as in individuals affected with Neurodevelopmental Disorders (Soden_2014) and Rhabdomyolysis (Vivante_2017), which are associated phenotypes for Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase. These data indicate that the variant is very likely to be associated with disease. Recombinant proteins purified from E.coli cultures showed the variant had reduced hydrolysis activity (25%) and reduced synthesis activity (34%) as compared to wild-type (Beluzic_2006). The following publications have been ascertained in the context of this evaluation (PMID: 16435181, 15024124, 16872278, 16736098, 25473036, 28779239). Six ClinVar submitters have assessed the variant since 2014: four classified the variant as likely pathogenic and two as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 15, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 23, 2004 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 25, 2023 | This variant is present in population databases (rs121918608, gnomAD 0.02%). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 143 of the AHCY protein (p.Tyr143Cys). For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects AHCY function (PMID: 16872278). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt AHCY protein function. This missense change has been observed in individual(s) with clinical features of S-adenosylhomocysteine hydrolase deficiency (PMID: 15024124, 16736098, 28779239, 33072517). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 12953). - |
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 10, 2023 | Published functional studies of enzymatic assays showed that this variant reduced hydrolysis and synthesis to 25% and 34% of wildtype, suggesting a damaging effect (Beluzic et al., 2006); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28647132, 34426522, 31589614, 28779239, 15024124, 18211827, 16736098, 33072517, 26095522, 16872278, 35463910) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | May 19, 2014 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
Rhabdomyolysis Pathogenic:1
Likely pathogenic, no assertion criteria provided | literature only | Yale Center for Mendelian Genomics, Yale University | Aug 05, 2017 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 15, 2017 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
M;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D
REVEL
Pathogenic
Sift
Uncertain
D;D
Sift4G
Uncertain
D;D
Polyphen
D;.
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at